• 1
    Subcommittee on Definition and Prevalence of the 1984 Joint National Committee: Hypertension prevalence and the status of awareness, treatment, and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension 7, 457468 (1985)
  • 2
    Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic, and cardiovascular risks, US population data. Arch Intern Med 153, 598615 (1993)
  • 3
    1988 Joint National Committee: The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 148, 10231038 (1988)
  • 4
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. J Am Med Assoc 213, 11431152 (1970)
  • 5
    Cutler JA, MacMahon SW, Furberg CD: Controlled clinical trials of drug treatment for hypertension. A review. Hypertension 13 (suppl I), I-36I-44 (1989)
  • 6
    Gallup G Jr, Cotugno HE: Preferences and practices of Americans and their physicians in antihypertensive therapy. Am J Med 81 (suppl II), 2024 (1986)
  • 7
    German PS: Compliance and chronic disease. Hypertension II (suppl II), 5660 (1988)
  • 8
    Lüscher TF, Vetter W: Adherence to medication. J Hum Hypertens 4 (suppl I), 4346 (1990)
  • 9
    Haynes RB: A critical review of the determinants of patient compliance with therapeutic regimens. In Compliance With Therapeutic Regimens (Eds. SackettDL, HaynesRB). Johns Hopkins University Press. Baltimore (1976) 2639
  • 10
    Monk M: Blood pressure awareness and psychological well-being in the Health and Nutrition Examination Survey. Clin Invest Med 4, 183189 (1981)
  • 11
    Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL, Williams GH: The effects of antihypertensive therapy on the quality of life. N Engl J Med 314, 16571664 (1986)
  • 12
    Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA: Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 13, 489495 (1991)
  • 13
    Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150, 18811884 (1990)
  • 14
    Mengden T, Binswanger B, Spühler T, Weisser B, Vetter W: The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day. morning versus evening. J Hypertens 11, 14031411 (1993)
  • 15
    Skaer TL, Sclar DA, Markowski DJ, Won JKH: Effect of valueadded utilities on prescription refill compliance and health care expenditures for hypertension. J Hum Hypertens 7, 515518 (1993)
  • 16
    Skaer TL, Sclar DA, Markowski DJ, Won JKH: Utility of a sustained-release formulation for antihypertensive therapy. J Hum Hypertens 7, 519522 (1993)
  • 17
    Guerrero D, Rudd P, Bryant-Kosling C, Middleton BF: Antihypertensive medication-taking. Investigation of simple regimen. Am J Hypertens 6, 586592 (1993)
  • 18
    Maxwell MH, Frishman WH, Kong BW: Quality-of-life considerations for first-line antihypertensive therapy. Cardiovasc Rev Rep 15, 1722 (1994)
  • 19
    Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335, 827838 (1990)
  • 20
    Pool JL: Newer antihypertensive drugs: A glimpse into the future. Curr Opin Cardiol 8, 775779 (1993)
  • 21
    The Treatment of Mild Hypertension Research Group: The Treatment of Mild Hypertension Study: A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 151, 14131423 (1991)
  • 22
    Kaplan NM: Systemic hypertension: Therapy. In Heart Disease (Ed. BraunwaldE). W.B. Saunders, Philadelphia (1992) 852874
  • 23
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Propranolol in the treatment of essential hypertension. J Am Med Assoc 237, 23032310 (1977)
  • 24
    Dahlöf C, Dimenäs E: Side effects of b̃-blocker treatments as related to the central nervous system. Am J Med Sci 299, 236244 (1990)
  • 25
    Nidorf SM, Parsons RW, Thompson PL, Jamrozik KD, Hobbs MST: Reduced risk of death at 28 days in patients taking a b̃ blocker before admission to hospital with myocardial infarction. Br Med J 300, 7174 (1990)
  • 26
    Schmidt GR, Schuna AA, Goodfriend TL: Transdermal clonidine compared with hydrochlorothiazide as monotherapy in elderly hypertensive males. J Clin Pharmacol 29, 133139 (1989)
  • 27
    Jamieson A, Reid JL: New antihypertensive drugs and new approaches to hypertension. Curr Opin Cardiol 7, 789795 (1992)
  • 28
    Bauer JH: Angiotensin converting enzyme inhibitors. Am J Hypertens 3, 331337 (1990)
  • 29
    Schoenberger JA, Testa M, Ross AD, Brennan WK, Bannon JA: Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice. Arch Intern Med 150, 301306 (1990)
  • 30
    The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325, 293302 (1991)
  • 31
    Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L. Wedel H. on behalf of the CONSENSUS II Study Group: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinayian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327, 678689 (1992)
  • 32
    Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319, 8086 (1988)
  • 33
    Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. on behalf of the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327, 669677 (1992)
  • 34
    Weber MA: Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. Am J Hypertens 5 (12 pt 2), 247S251S (1992)